Our findings should potentially prompt an active screening for SOD1 mutations in all individuals with a new ALS diagnosis, including patients with an apparently sporadic disease presentation, especially after the recent authorization of Tofersen as an early access program to all ALS patients with SOD1 mutations. Here, SOD1 is linked to amyotrophic lateral sclerosis.